Literature DB >> 8155683

Liposome-complement interactions in rat serum: implications for liposome survival studies.

D V Devine1, K Wong, K Serrano, A Chonn, P R Cullis.   

Abstract

Serum complement opsonizes particles such as bacteria for clearance by the reticuloendothelial system. Complement has been reported to interact with liposomes and therefore may mediate the reticuloendothelial system clearance of liposomes. This study has used a rat serum model to define some of the characteristics of liposomes which modulate their ability to activate complement. Using functional hemolytic assays and C3/C3b crossed immunoelectrophoresis, we have demonstrated that liposomes activated rat complement in a dose-dependent manner with higher concentrations of liposomes activating higher levels of complement. The detection of complement activation required the inclusion of phospholipids bearing a net charge. Complement activation occurred via the classical pathway; no alternative pathway activation was detected. The presence of cholesterol contributed to complement activation in a dose-dependent manner. Phospholipid fatty acyl chain length did not influence complement activation while the introduction of unsaturated acyl chains markedly decreased levels of complement activation. Liposome size also influenced complement activation with 400 nm unilamellar vesicles more effectively activating complement than 50 nm vesicles for equivalent amounts of exposed lipid. These studies demonstrate that the composition of the liposome greatly affects the in vitro activation of rat serum complement and suggest that the biological half-life of liposomes in the circulation of rats may be altered by changing the liposome composition to reduce complement activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8155683     DOI: 10.1016/0005-2736(94)90231-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  41 in total

Review 1.  Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups.

Authors:  S M Moghimi; A C Hunter
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

2.  Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in Blood.

Authors:  Hanmant Gaikwad; Yue Li; Geoffrey Gifford; Ernest Groman; Nirmal K Banda; Laura Saba; Robert Scheinman; Guankui Wang; Dmitri Simberg
Journal:  Bioconjug Chem       Date:  2020-06-29       Impact factor: 4.774

3.  Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers.

Authors:  D R Anderson; C M Carthy; J E Wilson; D Yang; D V Devine; B M McManus
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 4.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

5.  Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles.

Authors:  Yang Liu; Yunxia Hu; Leaf Huang
Journal:  Biomaterials       Date:  2014-01-02       Impact factor: 12.479

6.  Characterization and in vivo testing of a heterogeneous cationic lipid-DNA formulation.

Authors:  J G Smith; T Wedeking; J H Vernachio; H Way; R W Niven
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

7.  Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia.

Authors:  D F Eierman; M Yagami; S M Erme; S R Minchey; P A Harmon; K J Pratt; A S Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

8.  Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

Authors:  Yvonne Klapper; Osama A Hamad; Yuji Teramura; Gero Leneweit; G Ulrich Nienhaus; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Biomaterials       Date:  2014-01-23       Impact factor: 12.479

9.  Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.

Authors:  J Nieto; J Alvar; A B Mullen; K C Carter; C Rodríguez; M I San Andrés; M D San Andrés; A J Baillie; F González
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Nano to micro delivery systems: targeting angiogenesis in brain tumors.

Authors:  Ariel Gilert; Marcelle Machluf
Journal:  J Angiogenes Res       Date:  2010-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.